Loading stock data…
Lantheus Holdings (LNTH)
$104.82+1.09 (+1.05%)
Market ClosedLast close Jul 24
Lantheus Holdings, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lantheus Holdings, Inc. in the Healthcare sector is trading at $104.82 with a market capitalization of $6.9B. Wall Street consensus targets $112.33 (12 analysts), implying a +7.2% move over the next 12 months. The stock is currently near its 52-week high of $111.86, remaining 35.6% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +7.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $377.33M↓ | $406.79M↑ | $384.01M↑ | $378.05M↑ | $372.76M |
| Gross Profit | $230.92M↓ | $240.88M↑ | $222.37M↓ | $241.01M↑ | $237.70M |
| Operating Income | $81.33M↑ | $77.18M↑ | $43.62M↓ | $87.97M↓ | $106.79M |
| Net Income | $118.42M↑ | $54.09M↑ | $27.77M↓ | $78.75M↑ | $72.94M |
Peer Comparison
JNJUNHPFE
Fundamentals
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultras...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.95B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
23.02%
Volume
Today's trading volume
449,291
Recent News
1 Unpopular Stock That Deserves a Second Chance and 2 We Ignore
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
3 Reasons to Avoid LNTH and 1 Stock to Buy Instead
What a fantastic six months it’s been for Lantheus. Shares of the company have skyrocketed 60.5%, hitting $105.30. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
1 Small-Cap Stock with Competitive Advantages and 2 We Brush Off
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
Healthcare Equipment and Supplies Stocks Q1 Teardown: Lantheus (NASDAQ:LNTH) Vs The Rest
Looking back on healthcare equipment and supplies stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Lantheus (NASDAQ:LNTH) and its peers.
3 Healthcare Stocks with Open Questions
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have seen decent returns lately as healthcare stocks were up 6.4% over the past six months, almost identical to the S&P 500.